OTLK
Outlook Therapeutics (OTLK)
$47
About Outlook Therapeutics (OTLK)
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
Details
Daily high
$2.49
Daily low
$2.16
Price at open
$2.16
52 Week High
$3.39
52 Week Low
$0.79
Market cap
96.4M
Dividend yield
0.00%
Volume
3.1M
Avg. volume
2.9M
P/E ratio
-1.99
Outlook Therapeutics News
Details
Daily high
$2.49
Daily low
$2.16
Price at open
$2.16
52 Week High
$3.39
52 Week Low
$0.79
Market cap
96.4M
Dividend yield
0.00%
Volume
3.1M
Avg. volume
2.9M
P/E ratio
-1.99